Association between ADAMTS13 polymorphisms and risk of cardiovascular events in chronic coronary disease


Autoria(s): SCHETTERT, Isolmar T.; PEREIRA, Alexandre C.; LOPES, Neuza H.; HUEB, Whady A.; KRIEGER, Jose E.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

19/10/2012

19/10/2012

2010

Resumo

Introduction: Association between ADAMTS13 levels and cardiovascular events has been described recently. However, no genetic study of ADAMTS13 in coronary patients has been described. Materials and Methods: Based on related populations frequencies and functional studies, we tested three ADAMTS13 polymorphisms: C1342G (Q448E), C1852G (P618A) and C2699T (A900V) in a group of 560 patients enrolled in the Medical, Angioplasty, or Surgery Study II (MASS II), a randomized trial comparing treatments for patients with coronary artery disease (CAD) and preserved left ventricular function. The incidence of the 5-year end-points of death and death from cardiac causes, myocardial infarction, refractory angina requiring revascularization and cerebrovascular accident was determined for each polymorphim`s allele, genotype and haplotype. Risk was assessed with the use of logistic regression and Cox proportional-hazards model and multivariable adjustment was employed for possible confounders. Results: Clinical characteristics and received treatment of each genotype group were similar at baseline. In an adjusted model for cardiovascular risk variables, we were able to observe a significant association between ADAMTS13 900V variant and an increased risk of death (OR: 1,92 CI: 1,14-3,23, p = 0,015) or death from cardiac cause (OR: 2,67, CI: 1,59-4,49, p = 0,0009). No association between events and ADAMTS13 Q448E or P618A was observed. Conclusions: This first report studying the association between ADAMTS13 genotypes and cardiovascular events provides evidence for the association between ADAMTS13 900V variant and an increased risk of death in a population with multi-vessel CAD. (C) 2009 Elsevier Ltd. All rights reserved.

Sociedade de Cardiologia do Estado de Sao Paulo

Identificador

THROMBOSIS RESEARCH, v.125, n.1, p.61-66, 2010

0049-3848

http://producao.usp.br/handle/BDPI/21814

10.1016/j.thromres.2009.03.008

http://dx.doi.org/10.1016/j.thromres.2009.03.008

Idioma(s)

eng

Publicador

PERGAMON-ELSEVIER SCIENCE LTD

Relação

Thrombosis Research

Direitos

restrictedAccess

Copyright PERGAMON-ELSEVIER SCIENCE LTD

Palavras-Chave #ADAMTS13 #Chronic Coronary Disease #Polymorphism #Von Willebrand #Cardiovascular risk factor #MASS II trial #VON-WILLEBRAND-FACTOR #THROMBOTIC THROMBOCYTOPENIC PURPURA #ACUTE MYOCARDIAL-INFARCTION #CLEAVING PROTEASE ADAMTS13 #CONTROLLED CLINICAL-TRIAL #3 THERAPEUTIC STRATEGIES #ARTERY-DISEASE #GENETIC SUSCEPTIBILITY #MASS-II #MUTATIONS #Hematology #Peripheral Vascular Disease
Tipo

article

original article

publishedVersion